Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.
Yi-Hsin ChanTze-Fan ChaoShao-Wei ChenYi-Wei KaoChien-Ying HuangPao-Hsien ChuPublished in: European heart journal. Quality of care & clinical outcomes (2022)
A modest increase in serum creatinine (<30%) was common following SGLT2i initiation, and was not associated with worse clinical outcomes, therefore should not stop therapy prematurely, but a larger increase in creatinine following drug therapy was not typical and should raise concern and review of the patient.